These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36264603)

  • 1. GPRASP1 is a candidate anti-oncogene and correlates with immune microenvironment and immunotherapeutic efficiency in head and neck cancer.
    Zhang T; Liu G; Zhang J; Chen S; Deng Z; Xie M
    J Oral Pathol Med; 2023 Mar; 52(3):232-244. PubMed ID: 36264603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
    Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
    Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
    Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
    World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
    Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z
    Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
    Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
    World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
    Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
    J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Expression of RTN1 in Lung Adenocarcinoma and 
Its Effect on Immune Microenvironment].
    Zhu S; Zu L; Xu S
    Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
    Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
    Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
    Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
    J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer.
    Pu S; Zhou Y; Xie P; Gao X; Liu Y; Ren Y; He J; Hao N
    Front Immunol; 2022; 13():964118. PubMed ID: 36059470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
    Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
    Front Immunol; 2022; 13():969034. PubMed ID: 36466881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.